Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-10-29 Proxy Solicitation & In…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
KALLELSE TILL EXTRA BOLAGSSTÄMMA I SYNACT PHARMA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice ('Kallelse') for an Extraordinary General Meeting (Extra bolagsstämma) for SynAct Pharma AB. It contains the agenda, proposals for board decisions (such as the ESOP 2025 incentive program), and instructions for shareholders to participate. This falls under the category of materials provided to shareholders for a meeting, which is classified as Proxy Solicitation & Information Statement.
2025-10-29 Swedish
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SYNACT PHARMA AB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice to Attend the Extraordinary General Meeting' for SynAct Pharma AB. It contains the agenda, proposed resolutions (specifically regarding an employee share option program), and instructions for shareholders to participate or vote by proxy. This document is a classic proxy statement/notice of meeting sent to shareholders to solicit their participation and votes for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-10-29 English
Förslag till beslut om bemyndigande för styrelsen att besluta om förvärv och överlåtelse av egna aktier
Share Issue/Capital Change Classification · 100% confidence The document is a press release from SynAct Pharma AB announcing a proposal for the board to be authorized to acquire and transfer the company's own shares (share buyback program). While it discusses share repurchases, it is an announcement of a proposal to be voted on at a future Extraordinary General Meeting, rather than a report of a completed transaction or a formal proxy statement. Given the nature of the announcement regarding a future meeting and the inclusion of a link to the full proposal document, it fits best as a Regulatory Filing (RNS) or a general corporate announcement.
2025-09-29 Swedish
Proposal for a resolution on authorization for the Board of Directors to resolve on acquisition and transfer of own shares
Transaction in Own Shares Classification · 98% confidence The document is a press release announcing a proposal by the Board of Directors to seek shareholder authorization at an upcoming Extraordinary General Meeting (EGM) for the acquisition and transfer of the company's own shares. While it discusses share buybacks, it is not the actual execution of a transaction (POS) nor a formal proxy statement (PSI) itself, but rather an announcement of a proposal that will be detailed in a future notice. Given the document length and the explicit 'Attachments' section linking to the formal proposal, this fits the definition of a Report Publication Announcement (RPA) or a general regulatory announcement regarding upcoming corporate governance actions.
2025-09-29 English
SynAct Pharma’s CFO Björn Westberg leaves for new leading position
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of the company's CFO, Björn Westberg. This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2025-09-16 English
SynAct Pharmas CFO Björn Westberg slutar för ny ledande befattning
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of the company's Chief Financial Officer (CFO). This falls under the category of changes in senior management. According to the provided definitions, announcements regarding changes in the board of directors or senior management are classified as MANG.
2025-09-16 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.